A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Deepak L Bhatt, Keith A Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel StegSteven R Steinhubl, Michael A Weber, Joan Booth, Eric J Topol, CHARISMA Investigators

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)


The manifestations of atherothrombosis such as myocardial infarction, ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden. Additional therapies to decrease ischemic events in patients with established vascular disease or at risk for developing vascular disease are necessary. We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis.
Original languageEnglish
Pages (from-to)401.e1
JournalAmerican Heart Journal
Issue number3
Publication statusPublished - Sep 2005


  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Ischemia
  • Cardiovascular Diseases
  • Coronary Disease
  • Female
  • Humans
  • Ischemia
  • Leg
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Risk Factors
  • Ticlopidine

Cite this